Literature DB >> 21672084

In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii.

X Vila-Farres1, C Garcia de la Maria, R López-Rojas, J Pachón, E Giralt, J Vila.   

Abstract

At present, colistin is among the few antibiotics effective against Acinetobacter baumannii clinical isolates. However, in the last few years, colistin-resistant A. baumannii strains have been isolated. Therefore, antibiotics effective against these usually pan-resistant colistin-resistant A. baumannii strains are required. The main objective of this study was to analyse the activity of 15 peptides against colistin-susceptible and colistin-resistant A. baumannii. The MICs were determined by microdilution. Among these 15 antimicrobial peptides (AMPs), melittin, indolicidin and mastoparan showed good activity against both colistin-susceptible and colistin-resistant A. baumannii. Further studies of mastoparan with time-killing curves showed bactericidal activity at MIC ×8 for both colistin-susceptible and colistin-resistant A. baumannii. In conclusion, mastoparan may be a potential alternative for the treatment of colistin-resistant A. baumannii infections.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21672084     DOI： 10.1111/j.1469-0691.2011.03581.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


  30 in total

1.  In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogens.

Authors:  Michael Hornsey; Christopher Longshaw; Lynette Phee; David W Wareham
Journal:  Antimicrob Agents Chemother       Date:  2012-04-09       Impact factor: 5.191

2.  Highly synergistic activity of melittin with imipenem and colistin in biofilm inhibition against multidrug-resistant strong biofilm producer strains of Acinetobacter baumannii.

Authors:  Ali Mohammadi Bardbari; Mohammad Reza Arabestani; Manoochehr Karami; Fariba Keramat; Hossein Aghazadeh; Mohammad Yousef Alikhani; Kamran Pooshang Bagheri
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-01-20       Impact factor: 3.267

3.  In vitro activity of Protegrin-1, alone and in combination with clinically useful antibiotics, against Acinetobacter baumannii strains isolated from surgical wounds.

Authors:  Gianluca Morroni; Oriana Simonetti; Andrea Brenciani; Lucia Brescini; Wojciech Kamysz; Elzbieta Kamysz; Damian Neubauer; Miriam Caffarini; Monia Orciani; Eleonora Giovanetti; Annamaria Offidani; Andrea Giacometti; Oscar Cirioni
Journal:  Med Microbiol Immunol       Date:  2019-06-18       Impact factor: 3.402

4.  Lipopolysaccharide-deficient Acinetobacter baumannii shows altered signaling through host Toll-like receptors and increased susceptibility to the host antimicrobial peptide LL-37.

Authors:  Jennifer H Moffatt; Marina Harper; Ashley Mansell; Bethany Crane; Timothy C Fitzsimons; Roger L Nation; Jian Li; Ben Adler; John D Boyce
Journal:  Infect Immun       Date:  2012-12-17       Impact factor: 3.441

5.  In Vitro Activity of the Novel Antimicrobial Peptide Dendrimer G3KL against Multidrug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa.

Authors:  João Pires; Thissa N Siriwardena; Michaela Stach; Regula Tinguely; Sara Kasraian; Francesco Luzzaro; Stephen L Leib; Tamis Darbre; Jean-Louis Reymond; Andrea Endimiani
Journal:  Antimicrob Agents Chemother       Date:  2015-10-12       Impact factor: 5.191

6.  Therapeutic Potential of Novel Mastoparan-Chitosan Nanoconstructs Against Clinical MDR Acinetobacter baumannii: In silico, in vitro and in vivo Studies.

Authors:  Afreenish Hassan; Aamer Ikram; Abida Raza; Sidra Saeed; Rehan Zafar Paracha; Zumara Younas; Muhammad Tahir Khadim
Journal:  Int J Nanomedicine       Date:  2021-06-01

7.  The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace.

Authors:  Ignasi Roca; Paula Espinal; Xavier Vila-Farrés; Jordi Vila
Journal:  Front Microbiol       Date:  2012-04-23       Impact factor: 5.640

8.  Anti-candidal activity of a novel peptide derived from human chromogranin A and its mechanism of action against Candida krusei.

Authors:  Rui-Fang Li; Xiao-Hui Yan; Yan-Bo Lu; Ya-Li Lu; Hui-Ru Zhang; Shi-Hua Chen; Shuai Liu; Zhi-Fang Lu
Journal:  Exp Ther Med       Date:  2015-09-07       Impact factor: 2.447

9.  Antimicrobial properties and membrane-active mechanism of a potential α-helical antimicrobial derived from cathelicidin PMAP-36.

Authors:  Yinfeng Lv; Jiajun Wang; He Gao; Zeyun Wang; Na Dong; Qingquan Ma; Anshan Shan
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

10.  In vitro and in vivo toxicity and antibacterial efficacy of melittin against clinical extensively drug-resistant bacteria.

Authors:  Parvin Askari; Mohammad Hasan Namaei; Kiarash Ghazvini; Mehran Hosseini
Journal:  BMC Pharmacol Toxicol       Date:  2021-07-14       Impact factor: 2.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.